Literature DB >> 25448468

Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.

Tomoaki Higashiyama1, Yasuhiro Nishida, Katsutaro Morino, Satoshi Ugi, Yoshihiko Nishio, Hiroshi Maegawa, Masahito Ohji.   

Abstract

PURPOSE: To quantitatively evaluate the efficacy of methylprednisolone pulse therapy for extraocular muscle inflammation in thyroid-associated ophthalmopathy (TAO) using the short-tau inversion-recovery (STIR) technique of magnetic resonance imaging (MRI).
METHODS: The signal intensities of the superior rectus (SR), inferior rectus (IR), lateral rectus (LR), medial rectus (MR), and superior oblique (SO) muscles were measured using the STIR images from 34 eyes of 17 patients with TAO before and after methylprednisolone pulse therapy and 19 eyes of 19 controls. The signal intensity ratio (SIR) of the signal intensity in muscles to that in brain white matter was calculated.
RESULTS: The mean SIRs of the controls were 1.08 ± 0.26 in the SR, 1.32 ± 0.29 in the IR, 1.34 ± 0.19 in the LR, 1.47 ± 0.25 in the MR, and 1.28 ± 0.22 in the SO muscles. SIRs exceeding 2.0 were out of the normal range. The SIRs of the patients with TAO before treatment were 2.19 ± 0.64, 2.44 ± 0.58, 1.96 ± 0.43, 2.24 ± 0.47, and 1.91 ± 0.42, respectively, which was significantly (P < 0.001) higher than those of the controls; after treatment, the mean SIRs were 1.82 ± 0.57, 1.81 ± 0.49, 1.64 ± 0.35, 1.88 ± 0.43, and 1.54 ± 0.33, respectively, significantly (P < 0.001) lower in all muscles than those before treatment. However, the SIRs of some muscles remained over 2.0. Moreover, all cases that had deterioration of TAO had one or more muscles with a SIR exceeding 2.5 after treatment.
CONCLUSION: Extraocular muscle inflammation in TAO improved with treatment. However, inflammation in some muscles persisted after treatment, and a high SIR in the muscle after treatment suggested the risk of deterioration of TAO.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25448468     DOI: 10.1007/s10384-014-0365-x

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  31 in total

1.  Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.

Authors:  Kenji Ohtsuka; Akihiko Sato; Satoshi Kawaguchi; Masato Hashimoto; Yasuo Suzuki
Journal:  Jpn J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.447

2.  High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy.

Authors:  Ritva Kauppinen-Mäkelin; Anni Karma; Eeva Leinonen; Eliisa Löyttyniemi; Oili Salonen; Timo Sane; Kirsi Setälä; Jorma Viikari; Armin Heufelder; Matti Välimäki
Journal:  Acta Ophthalmol Scand       Date:  2002-06

3.  [Short-tau inversion-recovery (STIR) sequence magnetic resonance imaging evaluation of orbital structures in Graves' orbitopathy].

Authors:  N Rodríguez-González; C Pérez-Rico; R López-Para Giménez; J Arévalo-Serrano; B Del Amo García; L Calzada Domingo; L Flores Ruiz; R Blanco
Journal:  Arch Soc Esp Oftalmol       Date:  2011-09-09

4.  Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease.

Authors:  E J Mayer; D L Fox; G Herdman; J Hsuan; J Kabala; P Goddard; M J Potts; R W J Lee
Journal:  Eur J Radiol       Date:  2005-10       Impact factor: 3.528

5.  Magnetic resonance imaging of the optic nerve in optic neuritis.

Authors:  D H Miller; M R Newton; J C van der Poel; E P du Boulay; A M Halliday; B E Kendall; G Johnson; D G MacManus; I F Moseley; W I McDonald
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

6.  The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease.

Authors:  H B Hoh; R D Laitt; C Wakeley; J Kabala; P Goddard; M J Potts; R A Harrad
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

Review 7.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

8.  Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy.

Authors:  Naokata Yokoyama; Shigenobu Nagataki; Masataka Uetani; Kiyoto Ashizawa; Katsumi Eguchi
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

9.  Diagnostic accuracy of short-time inversion recovery sequence in Graves' Ophthalmopathy before and after prednisone treatment.

Authors:  Fabio Tortora; Mariaevelina Prudente; Mario Cirillo; Andrea Elefante; Maria Paola Belfiore; Francesco Romano; Salvatore Cappabianca; Carlo Carella; Sossio Cirillo
Journal:  Neuroradiology       Date:  2014-02-27       Impact factor: 2.804

10.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

View more
  14 in total

1.  Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2015-09-01       Impact factor: 2.447

2.  Dixon-T2WI magnetic resonance imaging at 3 tesla outperforms conventional imaging for thyroid eye disease.

Authors:  Alexis Ollitrault; Frédérique Charbonneau; Marie-Laure Herdan; Olivier Bergès; Kevin Zuber; Lama Giovansili; Pauline Launay; Julien Savatovsky; Augustin Lecler
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

3.  The effect of intravenous high-dose glucocorticoids and orbital decompression surgery on sight-threatening thyroid-associated ophthalmopathy.

Authors:  Yun Wen; Jian-Hua Yan
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

Review 4.  Extraocular muscle enlargement.

Authors:  Khizar Rana; Valerie Juniat; Sandy Patel; Dinesh Selva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.535

5.  Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy.

Authors:  Y Kaichi; K Tanitame; H Itakura; H Ohno; M Yoneda; Y Takahashi; Y Akiyama; K Awai
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-30       Impact factor: 3.825

6.  Usefulness of two-point Dixon T2-weighted imaging in thyroid-associated ophthalmopathy: comparison with conventional fat saturation imaging in fat suppression quality and staging performance.

Authors:  Lu Chen; Hao Hu; Huan-Huan Chen; Wen Chen; Qian Wu; Fei-Yun Wu; Xiao-Quan Xu
Journal:  Br J Radiol       Date:  2020-12-22       Impact factor: 3.039

7.  Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves' orbitopathy and analysis on who requires additional therapy.

Authors:  Theodora Tsirouki; Alexandra Bargiota; Stelios Tigas; Agathi Vasileiou; Eftichia Kapsalaki; Zoe Giotaki; Ioannis Asproudis; Agathokles Tsatsoulis; Georgios Koukoulis; Evangelia E Tsironi
Journal:  Clin Ophthalmol       Date:  2016-11-17

8.  Quantitative Analysis of Inflammation in Orbital Fat of Thyroid-associated Ophthalmopathy Using MRI Signal Intensity.

Authors:  Tomoaki Higashiyama; Maki Iwasa; Masahito Ohji
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

9.  Texture analysis of orbital magnetic resonance imaging for monitoring and predicting treatment response to glucocorticoids in patients with thyroid-associated ophthalmopathy.

Authors:  Yue-Yue Wang; Qian Wu; Lu Chen; Wen Chen; Tao Yang; Xiao-Quan Xu; Fei-Yun Wu; Hao Hu; Huan-Huan Chen
Journal:  Endocr Connect       Date:  2021-06-24       Impact factor: 3.335

10.  Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2016-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.